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Abstract
Streptococcus pneumoniae is the leading cause of respiratory acute infections around the world. In Latin America,
approximately 20,000 children under 5 years of age die of pneumococcal diseases annually. Pneumococcal surface protein A
(PspA) is among the best-characterized pneumococcal antigens that confer protection in animal models of pneumococcal
infections and, as such, is a good alternative for the currently available conjugated vaccines. Efficient immune responses
directed to PspA in animal models have already been described. Nevertheless, few low cost adjuvants for a subunit
pneumococcal vaccine have been proposed to date. Here, we have tested the adjuvant properties of the whole cell
Bordetella pertussis vaccine (wP) that is currently part of the DTP (diphtheria-tetanus-pertussis) vaccine administrated to
children in several countries, as an adjuvant to PspA. Nasal immunization of BALB/c mice with a combination of PspA5 and
wP or wPlow – a new generation vaccine that contains low levels of B. pertussis LPS – conferred protection against a
respiratory lethal challenge with S. pneumoniae. Both PspA5-wP and PspA5-wPlow vaccines induced high levels of systemic
and mucosal antibodies against PspA5, with similar profile, indicating no essential requirement for B. pertussis LPS in the
adjuvant properties of wP. Accordingly, nasal immunization of C3H/HeJ mice with PspA5-wP conferred protection against
the pneumococcal challenge, thus ruling out a role for TLR4 responses in the adjuvant activity and the protection
mechanisms triggered by the vaccines. The high levels of anti-PspA5 antibodies correlated with increased cross-reactivity
against PspAs from different clades and also reflected in cross-protection. In addition, passive immunization experiments
indicated that antibodies played an important role in protection in this model. Finally, subcutaneous immunization with a
combination of PspA5 with DTPlow protected mice against challenge with two different pneumococcal strains, opening the
possibility for the development of a combined infant vaccine composed of DTP and PspA.
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Introduction
Recent reports on Streptococcus pneumoniae burden worldwide
indicate that the health problems caused by this pathogen are far
from being solved [1,2]. The number of deaths caused by
pneumococcal diseases is still high in young children, reaching
about 1 million cases per year. Around 60% of these deaths occur
in developing countries [1]. The introduction of the seven-valent
pneumococcal conjugate vaccine (PCV7) has substantially pre-
vented the incidence of pneumococcal invasive diseases caused by
vaccine serotypes in developed countries such as the United States,
France and Canada [3,4] with extended benefits to non-
immunized individuals by the herd-immunity.
However, the introduction of the PCV7 also highlighted a
potential drawback of polysaccharide-based vaccines that is the
substitution of the prevalent serotypes for others that were not
included in the vaccine. An example of such effect is the
emergence of the serotype 19A as a prevalent cause of
pneumococcal diseases in countries where the PCV7 has been
introduced [5,6,7]. Inclusion of additional serotypes in available
conjugate vaccines is a natural step forward to the development of
new vaccines and is the rationale for the new 10- and 13- valent
versions of conjugated vaccines that are under process of licensing.
Certainly, serotype coverage displayed by these vaccines will vary
depending on the region of the world [8,9,10]; but major concerns
are related to the possibility of additional serotype substitution, as
has occurred within a few years of PCV7 use, and the high costs of
conjugated vaccines, especially when they are considered for use in
developing countries.
In the past years, several protein antigens have been proposed
as vaccine candidates aiming at the development of effective
broad-coverage formulations at low costs [11]. Among them, the
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studied. As a virulence factor, PspA has been implicated in evasion
from the immune system by inhibition of complement deposition
on bacterial surface [12,13] and binding to the mucosal
bactericidal protein apolactoferrin [14]. Several vaccine formula-
tions based on PspA have proven to be effective in animal models
of pneumococcal infections. Vaccine approaches include DNA
vaccines [15,16,17], antigen delivery by salmonella [18,19] and
lactic-acid bacteria vectors [20,21,22] or combination of recom-
binant proteins with Toll-like receptors agonists or cytokines
[23,24]. Taken together, the results of these publications indicate a
strong correlation between increased protection in animal models
and the induction of Th1 responses, characterized by high levels of
anti-PspA IgG2a and IFN-c production.
IL-17 secretion by CD4
+ T lymphocytes was also shown to be
an important branch of innate [25] and acquired immune
responses to pneumococcal infection induced by a cellular vaccine
[26] or vaccines based on pneumococcal cell wall polysaccharide
and recombinant proteins [27,28,29,30]. Using a PspA nasal
vaccine, we have also shown a correlation between increased
protection and secretion of IL-17 by lung and spleen cells, after a
lethal respiratory challenge in mice [22].
Research on adjuvants is a crucial matter of vaccine
development. Aluminum salts (Alum) have proven to be efficacious
for recombinant-protein based formulations in which Th2
responses are very effective. Still, several groups are focusing their
studies in describing new adjuvants for applications where cell
mediated immunity is desired [31]. Such responses are usually
induced by cellular vaccines, as the case of whole cell pertussis
vaccine (wP) [32,33,34,35]. In addition to the high efficacy of wP
against whooping cough, numerous works have described its
efficacy as adjuvant when administered in combination with
different antigens [36,37]. Cellular pertussis vaccines have
sometimes been associated with serious side effects in children.
Although causal relationship between wP vaccination and side
effects has not been well established [38], some countries adopted
acellular formulations that induce mild side effects but sometimes
display slightly reduced efficacy when compared with wP and have
higher production costs [38]. An increase in pertussis cases all over
the world has been observed in the recent years [39]. Proposed
alternatives for the available vaccines include administration of wP
through mucosal routes [40] as well as the use of attenuated B.
pertussis mutants [41].
In Brazil, more than 260 million doses of DTPw (Diphteria-
Tetanus-Whole Cell Pertussis) produced by Instituto Butantan
(Sa ˜o Paulo, Brazil) have been administered to children all over the
country since 1996, with no reports of serious side effects. In fact,
cost-effectiveness and safety results led the Pan American Health
Organization (PAHO) to conclude that there is no reason for Latin
American countries to change from wP to acellular formulations
[42].
In this work, we have hypothesized that a combination of PspA
with wP could trigger protective immune responses against
pneumococcal infections. A concern related with pneumococcal
vaccines composed of PspA is the variability of the protein in
pneumococcal isolates, which is the basis for its classification into 6
clades and 3 families [43]. Recently two studies from our group
have demonstrated that some fragments can induce antibodies
with cross-reactivity among PspAs from different clades and
isolates, reflecting in broad coverage vaccine formulations [44,45].
The experiments presented here were conducted with one of such
molecules, PspA5, and two different wP vaccines. The first one,
wP, is currently part of the Brazilian DTPw vaccine; the second, is
a new generation wP vaccine that contains low levels of LPS
(wPlow) and has recently undergone a phase 1 clinical trial [46].
Local and systemic immune responses were evaluated in mice
immunized through the nasal route with both PspA5-wP and
PspA5-wPlow formulations and challenged with an invasive
pneumococcal strain. The role of LPS in the adjuvant activity of
wP and the role of anti-PspA antibodies in protection were
analyzed. Combined vaccines were also tested for protection
against strains expressing heterologous PspAs. Finally, the
potential of a combined PspA5-DTPlow vaccine in mice was also
assessed.
Results
Nasal immunization of mice with PspA5 in combination
with wP protects mice from pneumococcal infection
BALB/c mice were immunized through the nasal route with
PspA5 alone or in combination with wP (PspA5-wP) and 21 days
later, were submitted to a respiratory challenge with a lethal dose
of the ATCC6303 pneumococcal strain. In this model, non-
immunized mice usually die 72 h after challenge [47]. As shown in
Table 1, significant protection was observed in the group
immunized with the PspA5-wP formulation, whereas 50%
protection was observed in mice immunized with PspA5 alone.
No protection was observed for non-immunized mice or mice
inoculated with wP.
The PspA5-wP vaccine, which induced 100% survival in mice,
was chosen for further studies using mice immunized with wP or
non-immunized mice as controls. Groups of 4 BALB/c mice were
immunized with each of these formulations through the nasal
route and then submitted to the respiratory challenge with the
ATCC6303 pneumococcal strain.
Pneumococcal loads in lung homogenates and blood and were
determined at different time points after challenge. As observed in
Figure 1, 3 h after challenge, pneumococcal counts were around
10
5 to 10
6 bacteria per lung homogenate. These numbers
progressively increased in non-immunized mice (A) or mice
immunized with wP (C), reaching a maximum around 10
7 to
10
9 bacteria per lung homogenate at 72 h. In contrast, after the
first time point at 3 hours, the numbers of pneumococci in the
lungs of mice immunized with PspA5-wP decreased continuously
until the bacteria were almost completely cleared at 21 days after
the challenge (E). High number of pneumococci could be
recovered from the blood of non-immunized mice or mice
immunized with wP, 72 h after challenge (Figure 1B and D,
respectively). These mice died few hours later. Immunization with
PspA5-wP prevented pneumococcal invasion to bloodstream
(Figure 1F).
Table 1. Survival of BALB/c mice after intranasal challenge
with S. pneumoniae ATCC6303 - adjuvant properties of wP.
alive/total % of survival P
*
Non-immunized 0/6 --
wP 1/6 16.6 1
PspA5 3/6 50 0.09
PspA5-wP 6/6 100 0.001
*Fisher exact test. Results are representative of three independent experiments.
doi:10.1371/journal.pone.0010863.t001
Combined wP-PspA Vaccine
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can also be induced by combination of PspA5 with wPlow
Since a new generation of cellular pertussis vaccine, with low
LPS content (wPlow), was shown to induce similar immune
responses against pertussis antigens when compared with conven-
tional wP in a phase 1 clinical trial [46], we decided to test this
formulation in combination with PspA5 against the respiratory
challenge with S. pneumoniae ATCC6303 in mice. Mice were
immunized through the nasal route, following the same protocol
used for PspA5-wP. As observed in Table 2, significant protection
against pneumococcal infection was observed only for the group
vaccinated with PspA5-wPlow (83.3% survival, P=0.007, when
Figure 1. Pneumococcal loads in lungs and sera. Lungs (A, C and E) and sera (B, D and F) from non-immunized BALB/c mice (Non) or mice
immunized with wP or PspA5-wP were collected at different time points after intranasal challenge with ATCC6303 pneumococcal strain (PspA5). CFU
were determined in four mice per group, after plating the samples in blood-agar. Circles represent individual mice and lines represent the mean for
each group. (d=days). In conditions where no bacteria were detected, 1 CFU was considered.
doi:10.1371/journal.pone.0010863.g001
Combined wP-PspA Vaccine
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nization with PspA5 induced partial protection, with 50% of mice
survival. Time course experiments performed with the PspA5-
wPlow vaccine produced results similar to those observed for
PspA5-wP. While pneumococcal loads in the lungs of non-
immunized mice or mice immunized with wPlow tended to
increase with time post-challenge, the levels observed in mice
immunized with PspA5- wPlow, progressively decreased. In
addition, the PspA5-wPlow vaccine also prevented bacteria
invasion to the bloodstream (data not shown).
PspA5-wP and PspA5wPlow vaccines induce high levels of
systemic and mucosal anti-PspA5 antibodies
Nasal immunization with PspA5 induced significant higher
levels of anti-PspA5 IgG in the sera of BALB/c mice when
compared with control groups. Still, the levels of anti-PspA5 IgG
induced by both PspA5-wP and PspA5-wPlow formulations were
even higher and also significantly different from the observed in
mice immunized with PspA5 alone (Figure 2A). Combination of
PspA5 with wP and wPlow favored the induction of relative higher
levels of IgG2a, resulting in lower IgG1:IgG2a ratios when
compared with PspA5 alone (Figure 2B). In addition, both PspA5-
wP and PspA5-wPlow formulations induced high levels of anti
PspA5 IgG and IgA in BALF, as observed in Figures 2C and 2D,
respectively.
Protection induced by the PspA5-wP vaccine is not
dependent on TLR4 activation
Since wPlow seems to act as adjuvant for PspA5 in a similar way
as wP, we decided to analyze the contribution of B. pertussis LPS in
the protection elicited by the PspA5-wP formulation. C3H/HeJ
mice, which display a point mutation in the tlr4 gene that
abrogates the receptor activity, were immunized through the nasal
route as described for BALB/c mice. C3H/HePas mice were used
as control mice strain for this experiment. Nasal immunization
with PspA5-wP induced significant higher anti-PspA5 IgG in sera
from both mice strains, when compared with PspA5 alone
(Figure 3A and B). Additionally, significant protection was
observed for both mice strains when animals were vaccinated
with PspA5-wP (Table 3, P=0.0001, when compared with control
groups). To elucidate if B. pertussis LPS could act as adjuvant in this
model through the activation of other receptors, such as TLR2, we
decided to perform an experiment using purified LPS from the B.
pertussis strain used in our work, in combination with PspA5 in
C3H/HeJ. Nevertheless, nasal immunization of mice with
PspA5+LPS elicited similar levels of anti-PspA5 IgG as immuni-
zation with PspA5 alone (Figure 3C). This formulation did not
confer protection against the respiratory pneumococcal challenge
in C3H/HeJ mice (Table 4).
Passive immunization of mice with sera from animals
vaccinated with PspA5-wP protects mice against
pneumococcal respiratory challenge with the ATCC6303
strain
The capacity of each serum to bind to pneumococcal surface
was evaluated by Flow Cytometry, using intact ATCC6303
bacteria. The fluorescence intensities were higher when bacteria
were incubated with sera from mice immunized with PspA5-wP
and PspA5-wPlow vaccines, when compared with sera from mice
immunized with PspA5 (Figure 4A), correlating with antibodies
levels. On the other hand, in vitro complement deposition on
bacteria surface was similar for sera from mice immunized with
PspA5 or the combinations PspA5-wP and PspA5-wPlow
(Figure 4B).
Since several days were necessary for complete pneumococcal
clearance in lungs, but bacteria did not reach the bloodstream of
vaccinated mice (Figures 1E and F), we tested whether sera from
immunized mice could confer any protection against pneumococ-
cal infection. Naı ¨ve mice received pooled sera collected from
different groups, as indicated in Figure 4C, in a 1:100 dilution, by
intraperitoneal route, 2 h before challenge. The results showed a
significant protection induced by sera from the PspA5-wP group,
resulting in 75% of mice survival (Figure 4C).
Increased anti-PspA antibodies levels induced by the
combination with wP improves cross-reactivity against
different PspAs
It has already been demonstrated that sera against the PspA5
fragment used in this work displayed cross reactivity with PspAs
from different clades and families [44,45]. In a panel of strains
commonly used in animal models of challenge, we confirmed these
results by western-blot of total pneumococcal protein extracts
using sera from mice immunized with PspA5 through the nasal
route, in the absence of adjuvants (Figure 5A). However, as can be
observed in Figure 5B, cross-reactivity was greatly improved in
sera from mice immunized with PspA5-wP.
Protection against pneumococcal colonization induced by
different PspA-based vaccines has already been described
[23,48]. In order to address the cross reactivity induced by the
PspA5-wP vaccine, we have decided to test its efficacy in a well
established model of nasopharyngeal colonization in C57Bl/6
mice with the 0603 pneumococcal strain, which expresses PspA
from clade 1. Immunization of C57Bl/6 mice resulted in the
induction of high levels of anti-PspA antibodies, as observed for
the other mice strains (data not shown). Moreover, nasal
immunization of mice with PspA5-wP conferred significant
protection against nasopharyngeal colonization of mice with the
0603 pneumococcal strain, (P=0.003; 0.01 and 0.001, when
comparing PspA5-wP vaccinated mice with non-immunized mice,
or mice immunized with wP or PspA5, respectively) (Figure 5C).
We then decided to test the effects of wP when using a PspA3 N-
terminal fragment, a molecule previously defined to induce sera
with low or no cross-reactivity against PspAs from different clades
[44,45]. Mice were immunized through the nasal route with
PspA3 or PspA3-wP, as described for PspA5, and sera were
collected for analysis. Flow cytometry experiments using the
ATCC6303 strain, which expresses PspA from clade 5, showed an
improvement in binding capacity for sera from mice immunized
with PspA3-wP (Figure 6A). These sera also induced in vitro
complement deposition on the surface of ATCC6303 pneumo-
coccal strain, whereas sera from mice immunized with PspA3 did
not (Figure 6B). Finally, the cross reactivity observed in vitro
correlated with superior protection of mice after the lethal
Table 2. Survival of BALB/c mice after intranasal challenge
with S. pneumoniae ATCC6303 – adjuvant properties of wPlow.
alive/total % of survival P
*
Non-immunized 0/6 --- ---
wPlow 0/5 --- 1
PspA5 3/6 50 0.09
PspA5-wPlow 5/6 83.3 0.007
*Fisher exact test. Results are representative of two independent experiments.
doi:10.1371/journal.pone.0010863.t002
Combined wP-PspA Vaccine
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of mice with PspA3 conferred survival to only 30% of mice, the
combination PspA3-wP induced 60% of survival (P=0.007, when
compared with non-immunized mice) (Table 5).
Combination of PspA5 with the DTPlow vaccine protects
mice against the respiratory lethal challenge with
different pneumococcal strains
Since our findings supported the use of PspA in combination
with cellular pertussis vaccines for protection against pneumococ-
cal infections, we decided to test the feasibility of using a
combination of PspA5 with the DTPlow vaccine in mice. After
one single subcutaneous dose composed of 5 mg of PspA5 alone or
in combination with DT or DTPlow (Figure 7A), higher levels of
anti-PspA5 IgG were observed in mice sera, when compared with
the respective controls. The formulation PspA5-DTPlow also
induced significantly higher levels of antibodies when compared
with PspA5 alone. Analysis of IgG subtypes showed that the
PspA5-DTPlow formulation induced slightly higher IgG2a levels
than the other vaccines, resulting in lower IgG1:IgG2a ratio
(Figure 7B). Most important, 100% of mice survival, after
challenge with the ATCC6303 strain, was observed in the group
immunized with one dose of the PspA5-DTPlow vaccine
(P=0.001, when compared with control groups) (Table 6).
Significant protection was also observed for the PspA5-DT
formulation, leading to 66% of mice survival (P=0.03, when
compared with control groups) (Table 6). Mice immunized with
the same formulations were also challenged with the A66.1 strain,
which expresses PspA2. In this case, significant protection (66.6%
of survival, P=0.03, when compared with control groups) was
only observed in the group immunized with PspA5-DTPlow
(Table 6).
Discussion
In countries where PCV7 vaccine was introduced, a significant
reduction in diseases caused by the pneumococcal serotypes
included in its formulation was observed [5,6,7]. However, after
some years of its use, the emergence of new serotypes as prevalent
causes of diseases was observed. Although this effect may not
exclusively be related to vaccination [49], novel conjugated
vaccines composed of more polysaccharides turned out to be
necessary for a sustained broad-coverage. Another important
consideration is that coverage varies in different parts of the world.
A recent study conducted in children attending day-care centers in
the city of Goiania, Brazil, estimated that serotype coverage for
PCV7 and PCV10 would be around 60%, whereas PCV13
introduction would result in 72% of serotype coverage. Undoubt-
edly, these numbers are higher in other places of the world [9,10].
These characteristics, associated with the high costs of the
conjugated vaccines are obstacles for their implementation in
developing countries.
PspA is a variable molecule present on the pneumococcal
surface. However, the distribution of PspA clades in pneumococcal
isolates from different regions seems to be similar [50,51] with an
incidence of almost 50% of PspAs belonging to family 1 and 50%
to family 2. PspA from family 3 is rarely present in pneumococcal
isolates. Usually, formulations are proposed for PspA vaccines
based on cross-reactivity among clades from the same family,
resulting in the inclusion of at least one component of each family
or fusion proteins [19,52]. In this study, we have chosen to work
with PspA5, based on the cross-reactivity and cross-protection
results previously described by our group [44,45].
Whole-cell pertussis vaccine was shown to induce specific T cell
responses and mucosal and systemic antibodies against pertussis
antigens after nasal immunization of human volunteers [33]. The
adjuvant properties of such vaccines also favor the combination
with other antigens, which could result in polyvalent formulations
that could confer protection against multiple infectious diseases,
with reduced number of injections. Immunization of mice with B.
pertussis cellular vaccines (alone or in DTP formulations) in
combination with influenza vaccines was shown to induce high
levels of antibodies against influenza and antigen-specific IL-2 and
IFN-c secretion [37,53,54]. A combination of DTPw and a
Hepatitis B vaccine (HBV) resulted in higher humoral response to
hepatitis in children in Slovakia, when compared with children
that received the HBV alone [55]. Due to the adjuvant properties
of DTPw, equivalent responses to Haemophilus influenzae type b
conjugate vaccine (Hib) were observed in children that received
the vaccine alone or 1/10 of the dose directly diluted in DTPw
[56]. Simultaneous administration of PCV7 with a DTPw/IPV-
inactivated polio virus-/Hib vaccine was also shown to produce
satisfactory immune responses to pneumococcal polysaccharides in
French infants [57]. More detailed studies using an 11-valent
pneumococcal vaccine have demonstrated a reduced response to
pneumococcal polysaccharides when the vaccine was simulta-
neously administered with a DTPa/IPV/Hib vaccine. This effect
was not observed when the pertussis cellular component was used
[58]. In the present work, we have combined the PspA5 antigen
with a whole cell pertussis vaccine (wP), which is the pertussis
component of the current Brazilian DTPw vaccine, for tests as a
nasal formulation in mice. A robust protection against a lethal
respiratory challenge with the pneumococcal ATCC6303 strain
was observed in mice immunized with PspA5-wP.
Different cellular components are responsible for the adjuvant
effects of wP and are also believed to contribute to the adverse
effects observed [59,60,61]. Differences in LPS amounts among
vaccine formulations as well as the inactivation process during
vaccine manufacturing were some of the hypothesis raised to
explain differences in reactogenicity displayed by wP vaccines
produced by different countries. Still, controversies on this issue
persist to date and DTPw is administered to children in several
developing countries, inducing high levels of protection against
pertussis [38]. In an attempt to improve the acceptability of wP
vaccine, Instituto Butantan (Sa ˜o Paulo, Brazil) has developed a
methodology to remove the excess of LPS present in wP,
producing the wPlow. In the present work, we have also tested
the efficacy of wPlow as a mucosal adjuvant for PspA5. Similar
protection levels were observed for the PspA5-wPlow vaccine, when
compared with PspA5-wP. Overall, the immune responses
induced by both formulations seemed quite similar, with
controlled inflammatory responses elicited in lungs (manuscript
in preparation). This led us to test the role of B. pertussis LPS as the
determinant adjuvant component in our model. Combination of
Figure 2. Evaluation of anti-PspA5 antibodies in mice immunized with the different vaccine formulations. Three weeks after the last
immunization anti-PspA5 IgG (A), IgG1 and IgG2a (B) in the sera and IgG (C) and IgA (D) in BALF were detected through ELISA. Concentration of
antibodies (mean of 6 animals for A and B and 4 animals for C and D) are shown. IgG1:IgG2a ratios are indicated above the bars (B). Results are
representative of two experiments (A and B). Asterisks represent significant differences from control groups or from group immunized with PspA5,
when indicated (* P,0.05; ** P,0.005, Mann-Whitney U test).
doi:10.1371/journal.pone.0010863.g002
Combined wP-PspA Vaccine
PLoS ONE | www.plosone.org 6 May 2010 | Volume 5 | Issue 5 | e10863Figure 3. Induction of anti-PspA5 antibodies in C3H/HePas and C3H/HeJ mice. C3H/HePas (A) and C3H/HeJ (B and C) were immunized with
the different vaccine formulations through the nasal route. Three weeks after the last immunization anti-PspA5 IgG in the sera were detected through
ELISA. Concentration of antibodies (mean of 6 animals) is shown. Results are representative of two experiments. Asterisks represent significant
differences from control groups or from group immunized with PspA5, when indicated (* P,0.05; ** P,0.005, Mann-Whitney U test).
doi:10.1371/journal.pone.0010863.g003
Combined wP-PspA Vaccine
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concentrations in C3H/HePas and C3H/HeJ mice than PspA5
alone, indicating that the adjuvant activity was preserved in both
mouse strains. Moreover, in both cases, nasal immunization with
PspA5-wP induced protection against the lethal challenge with the
ATCC6303 strain. TLR4 responses were already shown to be
important for Th1 and Th17 responses induced by wP [32,62].
Conversely, purified B. pertussis LPS (properly named by the
authors as Lypooligosaccharide – LOS) were shown to induce in
vitro Th2-biased immune responses via TLR4 in human cells [63].
Monophosphoryl lipid A derived from the same B. pertussis strain
used in this work has already been shown to be a good adjuvant
for influenza vaccine [64]. It is possible that the residual LPS
present in wPlow contributes to the adjuvant properties and overall
protection observed in wild type mice; however, immune
responses directed to PspA5 in the absence of TLR4 are enough
to confer protection against the pneumococcal challenge. Other
components such as the Pertussis Toxin or the adenylate cyclase
toxin may be also acting as adjuvants to PspA5. The possibility
that the LPS derived from our B. pertussis strain could be activating
receptors other than TLR4 seemed not to be the case, since nasal
immunization of C3H/HeJ mice with PspA5 + LPS neither
increased the antibody levels induced by PspA5 alone nor
protected mice against pneumococcal challenge. In fact, it has
already been shown that LPS derived from other B. pertussis strains
stimulates TLR4 responses but are not able to induce TLR2
responses [63,65].
In BALB/c mice immunized through the nasal route with both
PspA5-wP and PspA5-wPlow, pneumococci were restricted to the
lungs. Sera from immunized mice presented high levels of anti-
PspA5 IgG, more balanced IgG1:IgG2a ratios and induced in vitro
complement deposition on pneumococcal surface. These condi-
tions were previously associated with increased protection elicited
by DNA vaccines composed of PspA [15] or intranasal vaccines
composed of PspA and IL-12 [24]. We thus decided to analyze if
the sera induced by PspA5-wP could elicit protection against the
pneumococcal lethal challenge. Passive immunization experiments
conducted in BALB/c mice have shown that the antibodies
produced by nasal immunization with PspA5-wP conferred
protection to naı ¨ve mice against the pneumococcal challenge.
This result suggests that although cellular responses can improve
the quality of the immune response against the respiratory
pneumococcal challenge in mice, leading to better protection, a
condition where high levels of anti-PspA5 antibodies are present
can be sufficient to induce significant protection. The high levels of
antibodies induced by the combination of wP with PspA5 also
reflected in increased cross-reactivity of the sera against PspAs
from different strains and clades. As a result, significant protection
against pneumococcal nasal colonization by a strain that expresses
PspA from clade 1 was also observed in C57Bl/6 mice immunized
with PspA5-wP through the nasal route. Moreover, combination
of wP with a PspA from clade 3, which was previously shown to
induce antibodies with poor or no cross-reactivity against PspAs
from other clades [44,45], greatly improved serum reactivity
against the ATCC6303 strain, increased complement deposition
onto bacterial surface and induced significant protection.
Several groups have proposed the nasal immunization of wP as
an alternative to decrease the possible side effects elicited by the
vaccines in infants or as strategies for boosters in young adults. The
present work shows that wP can also be a potent adjuvant to PspA,
when administered through the nasal route, conferring protection
against pneumococcal infection in mice. However, approved
DTPw vaccines are administered to children through the
intramuscular route. For this reason, we decided to analyze if
DTPlow, a new generation DTPw vaccine, could also improve
immune responses and confer protection against pneumococcal
infection in mice, when combined with PspA5. We have observed
that a single immunization of mice with PspA5-DTPlow through
the subcutaneous route induced 100% survival against the
challenge with the ATCC6303 strain (which expresses PspA5)
and 66.6% survival against the challenge with the A66.1 strain
(which expresses PspA2). Improved protection against ATCC6303
strain was also observed when PspA5 was combined to DT,
although in a lesser extent than the observed for the PspA5-
DTPlow combination. In a previous publication we have shown
that immunization of mice with the same PspA5 fragment, in
combination with Al(OH)3 as adjuvant (which induces a Th2
response), resulted in 67% of protection against the respiratory
challenge with pneumococcal ATCC6303 strain [45]. This is very
similar to the protection observed when we combined PspA5 with
DT (66.6% protection, Table 6) which also has Al(OH)3 in its
formulation. It has already been shown that optimal responses
against pneumococci are achieved with PspA-based vaccines that
induce balanced IgG1:IgG2a levels [15,24] and we propose here
that wP is an adequate adjuvant to induce such responses. Prime-
boost protocols in which PspA5-DTPlow and PspA5-DT are
combined can be tested and this also opens the possibility of
inclusion of PspA5 in the DT vaccine given to adults.
Based on the results presented here, we propose that the
inclusion of a PspA molecule, defined by its ability to induce cross-
reactive antibodies against different PspAs, in the current DTPw
vaccine, constitutes an efficient strategy for a new vaccine against
pneumococcal infections, with broad-coverage and low-produc-
Table 4. Survival of C3H/HeJ mice after intranasal challenge
with S. pneumoniae ATCC6303 - combination of PspA and B.
pertussis LPS.
alive/total % of survival P
*
Non 0/7 --- ---
LPS 0/7 --- ---
PspA5 4/7 57 0.03
PspA5 + LPS 2/7 28.5 0.23
*Fisher exact test.
doi:10.1371/journal.pone.0010863.t004
Table 3. Survival of C3H/HePas and C3H/HeJ mice after
intranasal challenge with S. pneumoniae ATCC6303.
C3H/HePas alive/total % of survival P
*
Non-immunized 1/9 11.1 ---
wP 2/10 20 0.54
PspA5 4/10 40 0.18
PspA5- wP 10/10 100 0.0001
C3H/HeJ
Non-immunized 0/9 --- ---
wP 0/10 --- ---
PspA5 4/10 40 0.054
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Experiments are now being conducted to determine if the
inclusion of PspA5 would produce any effect on the immune
responses against the DTP antigens. Finally, in an attempt to
reproduce the immunization calendar of infants from developing
countries we will now study the inclusion of BCG in this model.
Materials and Methods
Ethics statement
This work was performed in mice. During all experiments,
animals were supplied with food and water ad libitum and
experimental protocols were previously approved by the Ethical
Committee for Animal Research of Butantan Institute, under the
license number 457/08.
Bacterial strains and growth conditions
S. pneumoniae strains were grown in Todd-Hewitt broth (Difco)
supplemented with 0.5% yeast extract (THY), at 37uC, without
shaking. Bacteria were always plated in blood agar and grown
overnight at 37uC before inoculation in THY. Stocks were
maintained at 280uC in THY containing 20% glycerol. The
ATCC6303 strain (serotype 3, PspA clade 5) was a kind gift from
Dr. Maria Cristina Brandileone (Instituto Adolpho Lutz, Sa ˜o
Paulo, Brazil) and the A66.1 strain was kindly provided by Dr.
David E. Briles (University of Alabama at Birmingham, USA).
Both strains were used for the lethal respiratory challenge. For
colonization experiments, pneumococcal strain 0603 (serotype 6B,
PspA clade 1) was a gift from Dr. Richard Malley (Childrens
Hospital, Harvard Medical School, MA, USA). For Western blot
analysis, the pneumococcal strains D39 (serotype 2, PspA clade 2)
kindly provided by Dr. David E. Briles, P2139 (serotype 6A, PspA
clade 2) [66] and TIGR4 (serotype 4, PspA clade 3) both kindly
provided by Dr. Jeffrey N. Weiser (University of Philadelphia
School of Medicine, USA) were used, in addition to ATCC6303
and 0603 strains.
Recombinant proteins and vaccine formulations
The N-terminal fragments of PspA from clade 5 and 3 (from
strains 122/02 and 259/98, respectively – Instituto Adolpho Lutz,
Sa ˜o Paulo, Brazil), were expressed in E. coli BL21 SI (Invitrogen)
and purified by chromatography as previously described [44]. The
Figure 4. Binding to pneumococcal surface, complement deposition and passive protection elicited by anti-PspA5 antibodies. Sera
from BALB/c mice immunized with PspA5 (dotted black lines), PspA5-wP (solid black lines) or PspA5-wPlow (solid dark gray lines) were tested for the
ability to bind to the pneumococcal surface (A) and to mediate C3 deposition (B). S. pneumoniae ATCC 6303(PspA5) was incubated with 2% (A) or
10% of each group serum (B). Sera from non-immunized animals (gray areas) and immunized with wP (solid light gray lines) or wPlow (dotted light
gray lines) were used as control. The median fluorescence of bacteria is shown for each sample. Data are representative of two independent
experiments. Naı ¨ve mice were inoculated trough the intraperitoneal route with a 1:100 dilution of each serum 2 h before pneumococcal challenge.
Survival was monitored until 10 days after challenge (C). ***P,0.001 when compared with control groups and P=0.004 when compared with mice
vaccinated with PspA5 by Fisher exact test. Data were composed with two independent experiments.
doi:10.1371/journal.pone.0010863.g004
Combined wP-PspA Vaccine
PLoS ONE | www.plosone.org 9 May 2010 | Volume 5 | Issue 5 | e10863whole cell pertussis vaccine (wP) used in this work is composed of
the whole bacteria inactivated with 0.2% formalin and is currently
produced by Instituto Butantan (Sa ˜o Paulo, Brazil). This vaccine is
used for the formulation of the DTPw vaccine (composed of
Diphtheria and Tetanus toxoids and inactivated whole cell
pertussis, in the presence of Al(OH)3). The DTPw produced by
Instituto Butantan is currently distributed by the Brazilian
Ministry of Health to children all over the country, for vaccination
at 2, 4 and 6 months of age. The wPlow is a new generation cellular
pertussis vaccine produced by Instituto Butantan by the removal of
great part of the B. pertussis LPS through extraction with organic
solvent and is the pertussis component of the DTPlow vaccine that
has just passed through a phase 1 clinical trial [46].
Immunization of mice and antibody responses
BALB/c mice were produced by the animal facility from
Universidade Federal de Sa ˜o Paulo (CEDEME). C3H/HePas and
C3H/HeJ mice were produced by the animal facility from
Faculdade de Medicina Veterina ´ria da Universidade de Sa ˜o Paulo.
C57Bl/6 mice were provided by the animal facility from Instituto
Butantan. For the lethal pneumococcal challenge model, immuni-
zationwasperformedingroupsof4 to6femaleBALB/cmiceand6
to 10 C3H/HePas and C3H/HeJ mice (males and females). Each
vaccine dose contained 5 ug of PspA5 or PspA3 alone or in the
presence of 1/8 of the Human wP, wPlow, DT (Diphtheria and
Tetanus and toxoids in a formulation that contains Al(OH3)) or
DTPlow (described above) doses. In these conditions, each dose of
wP, wPlow or DTPlow contained 0.5 mg of total pertussis mass. In
some experiments, purified B. pertussis LPS (10 mg/dose - produced
by Instituto Butantan) was also combined with PspA5. Before
formulation of all vaccines tested, residual LPS from E. coli, present
in PspA5 and PspA3 preparations was removed by triton X-114
extraction as previously described [67]. Nasal immunization was
conducted in mice previously anesthetized through the intraperi-
toneal (i.p.) route with 200 mL of a 0.2% xilazine and 0.5%
ketamine mixture. Vaccines were administered in a volume of 10 ml
on days 0, 3, 14, 17, 28 and 31 (total of 6 doses). For subcutaneous
immunization, mice received 1 dose of each vaccine in a volume
100 ml. For the pneumococcal colonization model, groups of 6
female C57Bl/6 mice were immunized through the nasal route as
described above. In all experiments, control groups that received
only the adjuvants or that were not immunized were included. Mice
were bled through the retrorbital plexus fifteen days after the last
immunization. Serum and bronchoalveolar lavage fluid (BALF)
(collected as described below) were evaluated for antibody levels
were by ELISA in plates coated with PspA5. The assay was
performed using goat anti-mouse IgG, IgA, IgG1 or IgG2a and
rabbitanti-goat conjugatedwithHRP (SouthernBiotech). Standard
curves were generated using mouse IgG, IgA, IgG1 and IgG2a
(Southern Biotech).
Figure 5. Cross-reactivity and cross protection induced by immunization of mice with PspA5-wP. Western-blot analyses were carried out
using total protein lysates from different pneumococcal strains and a 1:500 dilution of sera from BALB/c mice immunized with PspA5 (A) or PspA5-wP
(B). Mice were immunized through the nasal route with the different indicated vaccines. Three weeks after the last immunization mice were
challenged with the 0603 pneumococcal strain (PspA1) through the nasal route and CFU were determined in nasal washes, 5 days after challenge.
Circles represent individual pneumococcal loads and lines represent the mean for each mice group. Asterisks indicate significant differences when
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immunization experiments
For intranasal respiratory lethal challenge, immunized mice
were anesthetized through the intraperitoneal route with 200 mL
of a 0.2% xilazine and 1.0% ketamine mixture. ATCC6303 or
A66.1 pneumococcal strains were grown in THY until mid-log
phase (OD600nm=0.4) and aliquots were maintained at 280uC
until use. Animals were challenged 21 days after the last
immunization with 3610
5 CFU/animal (ATCC6303) or 1610
6/
animal (A66.1) in 50 mL of saline, inoculated into one nostril of
mice, with the help of a micropipette. Animals were observed for
10 days for survival records. For passive immunization experi-
ments, sera collected from immunized mice were pooled and
inactivated at 56uC for 30 min. Groups of 6 naı ¨ve BALB/c mice
were inoculated intraperitoneally with 500 mL of a 1:100 dilution
of each serum, 2 h prior challenge with the ATCC6303 strain.
Animals were observed for 10 days for survival records.
For nasopharyngeal colonization experiments, the 0603 strain
was also grown in THY until OD600nm=0.4 and aliquots were
maintained at 280uC until use. Twenty one days after the last
immunization, C57Bl/6 mice were anesthetized through the
intraperitoneal route with 200 mL of a 0.2% xilazine and 0.5%
ketamine mixture and received 5610
6 CFU in 10 mL of saline,
into both nostrils. Mice were sacrificed 5 days later and
pneumococcal loads were determined in nasal washes performed
as previously described [68], by plating serial dilutions of the
samples in blood agar and incubating the plates at 37uC for 18 h.
Bronchoalveolar lavage fluid (BALF) collection and
recovery of bacteria from blood and lungs
Twenty one days after the last immunization dose, mice were
sacrificed through injection of a lethal dose of urethane (15 mg per
10 g of body weight) to collect BALF samples. A catheter was
inserted into the trachea of the mice and lungs were rinsed with
0.5 mL of sterile PBS followed by an additional rinse with 1 mL of
PBS. The fluids from both rinses were pooled aliquoted and
maintained at 280uC for antibody analysis.
For pneumococcal recovery, immunized mice were sacrificed as
described above at different time points after challenge. Lungs
from each mouse were collected and disrupted in 1 mL of half
saline with the use of a cell strainer. Serial dilutions of lung
homogenates or blood (collected through the retroorbital plexus)
were plated on blood agar. Plates were incubated overnight at
37uC and CFU determined. Detection of 0 CFU was considered
1 CFU. The limit of detection was 100 CFU/mL in blood samples
and 5 CFU/animal in lung samples.
Antibody binding and complement deposition assays
S. pneumoniae ATCC6303 frozen stocks were plated on blood agar
overnight then grown in THY to OD600nm0.4–0.5 (,10
8 CFU/ml)
and harvested by centrifugation. Bacteria were washed, suspended in
PBS and incubated with 2% of pooled sera during 30 min at 37uC.
Samples were washed once with PBS before incubation with
fluorescein isothiocyanate (FITC)-conjugated anti-mouse IgG (Sig-
ma) for 30 min on ice. For complement deposition assays, sera were
Figure 6. Cross-reactivity induced by immunization of mice with PspA3-wP. Sera from mice immunized with PspA3 (dotted black lines) or
PspA3-wP (solid heavy black lines) were tested for the ability to bind to the pneumococcal surface (A) and to mediate C3 deposition (B). S.
pneumoniae ATCC 6303 (PspA5) was incubated with 2% (A) or 10% of each group serum (B). Sera from non-immunized animals (gray areas) and
immunized with wP (solid light gray lines) were used as control. The median fluorescence of bacteria is shown for each sample. Data are
representative of two independent experiments.
doi:10.1371/journal.pone.0010863.g006
Table 5. Survival of BALB/c mice after intranasal challenge
with S. pneumoniae ATCC6303 - Combination of PspA3 and
wP.
alive/total % of survival P
*
Non 0/9 --- ---
wP 0/10 --- ---
PspA3 3/10 30 0.12
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a concentration of 10%, at 37uC for 30 min. Samples were washed
once with PBS and incubated with 10% of normal mouse serum as
source of complement in Gelatin Veronal buffer (Sigma), at 37uCf o r
30 min. After washing, samples were incubated with FITC-
conjugated anti-mouse C3 IgG (MP Biomedicals) in PBS, for
30 min on ice. Samples were fixed with 2% formaldehyde after two
washing steps and stored at 4uC. Flow cytometry analysis was
conducted using FACSCalibur (Becton Dickinson), and 10,000 gated
events were recorded. The median of fluorescent bacteria were used
to compare the groups.
Western blot analysis
Western-blots were performed with soluble protein lysates from
the pneumococcal strains D39, P2139, TIGR4, ATCC6303 and
Figure 7. Evaluation of anti-PspA5 antibodies in mice immunized with the different vaccine formulations. Three weeks after the last
immunization anti-PspA5 IgG (A), IgG1 and IgG2a (B) in the sera were detected through ELISA. Concentration of antibodies (mean of 6 animals) is
shown. IgG1:IgG2a ratios are indicated above the bars (B). Results are representative of two experiments. Asterisks represent significant differences
from indicated groups (**P,0.005, when compared with non-immunized mice or with the respective control groups and *P,0.01, when compared
with mice immunized with PspA5, Mann-Whitney U test).
doi:10.1371/journal.pone.0010863.g007
Table 6. Survival of BALB/c mice after intranasal challenge with S. pneumoniae ATCC6303 or A66.1 strains, after subcutaneous
immunization.
ATCC6303 (serotype 3, PspA5) A66.1 (serotype 3, PspA2)
alive/total % of survival P
* alive/total % of survival P
*
Non 0/6 --- --- 0/5 --- ---
DT 0/6 --- --- 0/6 --- ---
DTPlow 0/6 --- --- 0/6 --- ---
PspA5 2/6 33.3 0.22 0/6 --- ---
PspA5 + DT 4/6 66.6 0.03 3/6 50 0.09
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bacteria were collected by centrifugation. Pellets were washed
once in PBS and then lysed by the incubation with 1:10 of the
initial volume of a 0.1% sodium deoxycholate/0.15 M sodium
citrate solution, for 10 min at 37
uC, as previously described [69].
Samples were separated by SDS-PAGE and transferred to
nitrocellulose membranes. Anti-PspA5 or anti-PspA5-wP antise-
rum was added in a dilution of 1:500, followed by incubation
with HRP-conjugated goat anti-mouse IgG (1:1000, Sigma).
Detection was performed with a chemiluminescent ECL kit (GE
HealthCare).
Statistical analysis
Differences in survival rates were analyzed by Fisher exact test.
Differences in antibody concentrations and pneumococcal loads in
nasal colonization experiments were analyzed by the Mann–
Whitney U test. In all cases, P#0.05 was considered significantly
different.
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